Inhibitors of Bruton's tyrosine kinase

A method for treating a lymphoma in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (A):

• wherein
• A is N;
• R1 is phenyl-O-aryl or phenyl-S-aryl;
• R2 and R3 are independently selected from H, lower alkyl and substituted lower alkyl;
• R4 is L3-X-L4-G, wherein,
• L3 is optional, and when present is a bond, optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl;
• X is optional, and when present is a bond, O, —C(═O), S, —S(═O), —S(═O)2, —NH, —NR9, —NHC(O), —C(O)NH, —NR9C(O), —C(O)NR9, —S(═O)2NH, —NHS(═O)2, —S(═O)2NR9—, —NR9S(═O)2, —OC(O)NH—, —NHC(O)O—, —OC(O)NR9—, —NR9C(O)O—, —CH═NO—, —ON═CH—, —NR10C(O)NR10—, heteroaryl, aryl, —NR10C(═NR11)NR10—, —NR10C(═NR11)—, —C(═NR11)NR10—, —OC(═NR11)—, or —C(═NR11)O—;
• L4 is optional, and when present is a bond, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle;
• or L3, X and L4 taken together form a nitrogen containing heterocyclic ring;
• G is
• wherein, R6, R7 and R8 are each independently H;
• each R9 is independently selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl;
• each R10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl;
• or
• two R10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring;
• or
• R9 and R10 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring;
• or
• each R11 is independently selected from H, —S(═O)2R8, —S(═O)2NH2, —C(O)R8, —CN, —NO2, heteroaryl, or heteroalkyl;
• or a pharmaceutically acceptable salt thereof.